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The recent paper in CMI by Reinert et al. [1]
presented interesting information on invasive
pneumococcal disease in adults in North-Rhine
Westphalia, Germany, which was collected pro-
spectively. It was reported that blood cultures
were obtained in 464 cases, and that 152 of these
(only 11 grew Streptococcus pneumoniae) were
positive. However, no information was provided
concerning the 141 non-pneumococci isolates.
These data are of extreme importance, as hardly
any data concerning bacteraemic community-
acquired pneumonia are available. It was also
reported that 112 of 464 patients were receiving
antibiotic treatment when the blood cultures were
inoculated. It would be interesting to know how
many of these 112 blood cultures were positive
and which pathogens were cultured.
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REPLY FROM PROFESSOR
REINERT
Our prospective population-based survey [1] of
invasive pneumococcal disease (IPD) among
adults in North-Rhine Westphalia, Germany,
included 202 of the 386 hospitals in the region,
and the 27 microbiological laboratories that sub-
mitted reports of IPD in these hospitals to the
National Reference Centre for Streptococci
(NRCS). In addition, the degree of under-report-
ing in this region was evaluated. All 27 laborat-
ories were asked to provide complete laboratory
records on all cases of IPD, and 16 were able to do
so. Data concerning all IPD isolates sent by each
of these 16 laboratories to the NRCS were linked
to the databases of each laboratory’s information
system. Moreover, in two additional studies, the
frequency of obtaining blood cultures, as well as
the incidence of previous antibiotic therapy, was
analysed in patients with community-acquired
pneumonia (CAP). For the year 2000, the fre-
quency of obtaining blood cultures was deter-
mined for patients admitted to three university
hospitals (Aachen, Du¨sseldorf and Cologne) with
CAP. In addition, in 2001, the frequency of
antibiotic treatment before blood cultures were
obtained from CAP patients was determined by a
detailed analysis of patient histories. As outlined
in our paper in CMI [1], all cases with the
diagnosis of CAP (all diagnostic positions on the
discharge summary) were identified retrospec-
tively on the basis of ICD-10 codes (J13, J15.9,
J18.0, J18.9). Cases were linked with data in the
laboratory information systems of each hospital’s
microbiological laboratory.
Outcome data were obtained for all patients
from the discharge files of the individual hospi-
tals. Therefore, we are not able to provide the
prospective data requested by Professor Shah.
However, we would like to share the retrospec-
tive data for the 152 cases with positive blood
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